Latest news with #EEG-based
![[Bio USA] SK Biopharmaceuticals CEO highlights resilience, open innovation amid global shifts](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F22%2Fnews-p.v1.20250622.6f347ba79b0f48699e57a8849a11dca7_T1.jpg&w=3840&q=100)
![[Bio USA] SK Biopharmaceuticals CEO highlights resilience, open innovation amid global shifts](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75){kind=small}
Korea Herald
22-06-2025
- Business
- Korea Herald
[Bio USA] SK Biopharmaceuticals CEO highlights resilience, open innovation amid global shifts
Korea Herald correspondent BOSTON — SK Biopharmaceuticals CEO Lee Dong-hoon underscored the company's preparedness for potential US tariff changes and emphasized the critical role of open innovation in shaping the future of global pharmaceuticals. 'We've weathered volatility in our share price over the past year, but the impact of potential price cuts has been minimal,' Lee said Thursday during a press conference on the sidelines of the 2025 Bio USA. 'Our direct-to-market sales model remains fundamentally solid.' He recalled a particularly tense moment earlier this year when shifting US tariff policies posed logistical challenges. In April, the company rushed to transport finished products from Canada into the US before a new tariff deadline. 'When the final truck finally cleared customs, everyone burst into applause,' he recounted. To prevent such risks from recurring, the company now assembles finished products in Canada and ensures shipments cross the border ahead of any policy changes. Looking ahead, SK Biopharmaceuticals is evaluating Puerto Rico as a potential US-based manufacturing site, leveraging its status as a US territory and pharmaceutical hub. 'Canada is cost-effective for now, but we're preparing for every scenario,' Lee said, noting the company's tariff risk is now 'close to zero' for the year. Lee also expressed confidence in the company's long-term growth. 'We've already announced our goal to hit 1 trillion won ($728 million) in sales by 2029, and we're on track,' he said, citing consistent profitability since last year. A cornerstone of SK Biopharmaceuticals' strategy is open innovation. Instead of relying solely on internal research and development, the company is partnering with universities, biotech firms and research institutions. 'Major global pharmaceutical firms are moving away from in-house basic research, and so are we. When you can collaborate and generate results at a fraction of the cost, your possibilities expand," he explained. The CEO emphasized the importance of tapping into underutilized technologies at US universities and biotech startups to diversify the company's pipeline, moving beyond its core focus on epilepsy into areas like oncology. Artificial intelligence is another major focus area. Lee highlighted the company's work on EEG-based seizure prediction models in collaboration with European and South American partners, along with AI algorithm development trials currently underway in Korea. 'AI is no longer optional. It's essential in every part of the business,' he said. One standout partnership is with PhnyX Lab, whose AI-driven automation of clinical documentation significantly reduced paperwork. 'Even our US team, which was initially skeptical, was blown away,' Lee said, calling the shift 'Copernican' in scale for how it will reduce time and cost. The CEO also outlined plans to build a global digital platform for epilepsy patients — a space where patients and physicians can share experiences and insights. 'It's not about selling drugs,' he clarified. 'It's about collecting data to inform AI-powered marketing, drug development and clinical trial design.' The company is looking three to five years ahead, aiming to build an ecosystem where shared data drives innovation across functions. In the US, SK Biopharmaceuticals is intensifying its engagement with health care providers. Lee has personally met with dozens of physicians this year, aiming for 100 meetings, to gather insights that will shape lifecycle strategies such as patent extensions, expanded indications and new formulations like IV delivery. Meanwhile, SK Biopharmaceuticals has invested in targeted TV and YouTube campaigns for its flagship epilepsy drug, Xcopri (cenobamate). Its 'Road to Reduction' campaign drew 9.37 million views in just one month, signaling the brand's growing visibility and leadership in the epilepsy treatment market.
Hindustan Times
12-06-2025
- Health
- Hindustan Times
Neurotech and brain data: New frontier of privacy concerns
Consumer neurotechnology is no longer confined to sci-fi or academic labs. Thanks to AI advancements and shrinking chip sizes, devices that read brain activity, like EEG headsets, mood-tracking earbuds, and brain-controlled gaming accessories are entering the mainstream. Since 2011, over 130 startups have jumped into the consumer neurotech space. These tools, often embedded in wearables, promise productivity boosts, mental health insights, and immersive control over AR/VR environments. Tech giants like Apple and Snap are already exploring brain-computer interfaces (BCIs) for future headsets that could respond to mental states in real time. How Neurotech Works—And why It's risky EEG-based devices dominate this landscape, powering nearly 65% of consumer neurotech products. They track brainwave patterns linked to emotions, focus, and engagement levels. That may sound harmless until you realise this data could be mined to predict behaviours, preferences, or even political leanings. Imagine hyper-targeted ads based not on clicks, but on neural spikes. Or worse, cognitive surveillance, where employers or governments monitor attention levels, emotional stress, or signs of dissent. Cyberattacks targeting BCIs could introduce 'mental hacks', altering thought patterns or inducing confusion and distress. As one expert puts it, 'Brain data reveals thoughts before they're consciously expressed.' Regulatory gaps and urgent challenges The legal protections around all this? Alarmingly thin. While medical neurotech is regulated (MRIs or brain implants), consumer-grade EEG headsets fall into a grey zone. In the U.S., the FDA only monitors medical devices. State laws in places like California and Colorado require user consent for neural data use, but there's little enforcement. Internationally, concerns are mounting: China has tested neurotech in workplaces to track employee fatigue, while neuromarketing firms tap EEG feedback to fine-tune advertisements. 'Neural data could be weaponized for psychological warfare or blackmail.' Path forward So what now? We need clear federal laws that define how brain data can be collected, stored, and shared. Users should know exactly what's being tracked and who has access to it. Neural data must be encrypted, just like financial or medical records. Most importantly, the public must be made aware of what 'brain transparency' really means. Because the future of privacy may no longer be in your hands, but in your head. First Published Date: 12 Jun, 21:23 IST
Iraqi News
18-02-2025
- Health
- Iraqi News
Meta's AI can now read your mind with 80% accuracy
INA - SOURCES Meta's AI research team is getting closer to decoding human thoughts. The company, in collaboration with the Basque Center on Cognition, Brain, and Language, has developed an AI model capable of reconstructing sentences from brain activity with up to 80% accuracy. The research relies on a non-invasive brain recording method and, according to the company, could pave the way for technology that helps people who have lost the ability to speak. Unlike existing brain-computer interfaces that often require invasive implants, Meta's approach uses magnetoencephalography (MEG) and electroencephalography (EEG). These techniques measure brain activity without surgery. The AI model was trained on brain recordings from 35 volunteers as they typed sentences. When tested on new sentences, Meta claims it can accurately predict up to 80% of the characters typed using MEG data—at least twice as effective as EEG-based decoding. This method still has limitations. MEG requires a magnetically shielded room, and participants must remain still for accurate readings. The technology has also only been tested on healthy individuals, so its effectiveness for those with brain injuries remains uncertain. Beyond decoding thoughts into text, Meta's AI is also helping researchers understand how the brain turns ideas into language. The AI model analyzes MEG recordings, tracking brain activity at a millisecond level. It reveals how the brain transforms abstract thoughts into words, syllables, and even individual finger movements when typing.
